Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada. Source
No articles found.
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading glo...
WuXi Biologics (stock code: 2269.HK), a Hong Ko...
Ansell Limited provides health and safety protection solutions. The Company has op...
Ansell Limited provides health and safety prote...
Verrica Pharmaceuticals Inc. is an innovative clinical-stage medical dermatology c...
Verrica Pharmaceuticals Inc. is an innovative c...
Our mission is to improve the lives of patients by developing novel, best-in-class...
Our mission is to improve the lives of patients...
We are a clinical stage biopharmaceutical company focused on harnessing powerful b...
We are a clinical stage biopharmaceutical compa...
We at Auris Medical are dedicated to developing novel pharmaceutical products for ...
We at Auris Medical are dedicated to developing...
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...
Cyclerion Therapeutics is a clinical-stage biop...
Join the National Investor Network and get the latest information with your interests in mind.